Analyst Price Target is $2.50
▲ +133.64% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ReWalk Robotics in the last 3 months. The average price target is $2.50, with a high forecast of $2.50 and a low forecast of $2.50. The average price target represents a 133.64% upside from the last price of $1.07.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in ReWalk Robotics. This Buy consensus rating has held steady for over two years.
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.